Corvus Pharmaceuticals

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) is a Burlingame, California-headquartered clinical-stage immuno-oncology biopharmaceutical company founded in 2014 by Richard Miller (former Pharmacyclics-and-Genentech executive). The company develops two principal clinical-stage assets: soquelitinib (CPI-818), an oral selective interleukin-2-inducible-T-cell-kinase (ITK) inhibitor in pivotal Phase 3 development for relapsed-refractory peripheral T-cell lymphoma (PTCL), with additional Phase 2 expansion in immune-cell-disease applications including atopic dermatitis-and-alopecia areata; and ciforadenant (CPI-444), an oral A2a-adenosine-receptor antagonist for renal-cell-carcinoma-and-prostate-cancer combination immunotherapy.

The 2024–2026 inflection: positive Phase 1/2 read-out for soquelitinib in PTCL showing approximately 28 percent objective-response-rate as monotherapy in heavily-pretreated patients, supporting the Phase 3 pivotal-trial design that initiated mid-2025. The Phase 3 top-line read-out is expected in H2 2027. Ciforadenant additionally received FDA Fast-Track designation for renal-cell-carcinoma in 2024. The 12,31 USD price reflects the post-Phase-1/2-read-out rally from approximately 4 USD in mid-2024 plus the structural-conviction-build through 2025–2026 as Phase 3 enrollment progresses.

Corvus has a high-conviction specialty-biotech institutional base. Bristol-Myers Squibb holds approximately 13,8 percent of shares (from 2018 strategic-collaboration-equity-investment) — the dominant strategic-anchor signalling continued interest in the ITK-inhibitor-and-adenosine-receptor-antagonist mechanism. Vivo Capital at approximately 11,2 percent, OrbiMed Advisors at approximately 9,7 percent, and RA Capital Management at approximately 5,4 percent represent the principal specialty-biotech-pipeline-thesis institutional holders. CEO Richard Miller holds approximately 4,3 percent of shares directly plus management-equity-plans. Short-interest sits at approximately 6,8 percent of float as of May 2026.

Corvus at 12,31 USD per share with approximately 84,1 million shares outstanding has a market capitalization of approximately 1,04 billion USD. With approximately 70 million USD cash and minimal debt, enterprise value is approximately 970 million USD. The forward-P/E is negative (~-15,9x) reflecting pre-revenue clinical-stage burn.

The Phase 3 soquelitinib read-out (expected H2 2027) is the dominant valuation-catalyst. A positive read-out supports peak-revenue trajectory of 600–900 million USD by 2030 and a risk-adjusted-DCF EV of approximately 1,8–2,8 billion USD, supporting a share-price range of 21–32 USD (70–160 percent upside). A negative read-out compresses to ciforadenant-only valuation of 3–5 USD. The bull-case (Phase 3 ORR exceeds 30 percent, BMS acquisition-bid) supports a 28–38 USD range over 24 months.

1. 2026 Q4:

   Phase 3 soquelitinib enrollment-completion-update and interim-data-disclosure (if pre-planned). Watch-items: enrollment-pace versus consensus, any safety-signal-update, BMS-collaboration-engagement update.

2. 2027 Q3:

   Phase 3 soquelitinib top-line read-out (expected H2 2027 per management guidance). This is the dominant single-event in the Corvus story. Positive read-out unlocks 21–32 USD range; negative compresses to 3–5 USD.

3. 2028 H1:

   FDA approval decision for soquelitinib (mid-to-late 2028 if Phase 3 positive, with Priority-Review potential). Successful approval plus commercial-launch supports 30–40 USD range.

Corvus Pharmaceuticals is a specialty-biotech-event-driven asset with high-conviction Phase 3 pivotal-trial-thesis in PTCL, Bristol-Myers-Squibb strategic-anchor providing mechanism-validation-and-acquisition-optionality, and a dual-asset-pipeline-platform that reduces but does not eliminate single-asset binary-risk. Position-sizing: 0,3–0,8 percent in thematic-biotech-event-driven sleeve, suitable only for investors with tolerance for binary clinical-trial-outcomes and 6–18 month patience to the Phase 3 read-out.